July 28, 2017 1:04 AM ET

Pharmaceuticals

Company Overview of CURE Pharmaceutical Holding Corp.

Company Overview

Cure Pharmaceutical Holding Corp., a specialty pharmaceutical and bioscience company, develops advanced oral thin films for the delivery of nutraceutical, over-the-counter (OTC), and prescription products for human and veterinary markets. It offers macustrip vitamin complex, ID life sleep melatonin, electrolyte, E6 berry caffeine, and hang-over relief products. The company is also developing aspirin, loratadine, tadalifil, sildenafil, loperamide, vitamin B12, vitamin D3, and folic acid products. Cure Pharmaceutical Holding Corp. is headquartered in Oxnard, California.

1620 Beacon Place

Oxnard, CA 93033

United States

1 Employees

Phone:

805-824-0410

Fax:

805-487-7163

Key Executives for CURE Pharmaceutical Holding Corp.

Chairman & CEO
Age: 50
Total Annual Compensation: $118.3K
President and Chief Scientific Officer
Age: 68
Total Annual Compensation: $37.5K
Chief Financial Officer, Treasurer and Secretary
Age: 40
Total Annual Compensation: $102.3K
Chief Operating Officer
Age: 56
Total Annual Compensation: $104.8K
Chief Business Officer
Age: 40
Compensation as of Fiscal Year 2016.

CURE Pharmaceutical Holding Corp. Key Developments

Cure Pharmaceutical & Therapix Biosciences Signs MOU with Assuta Medical Center to Develop Therapeutic Products in Fields of Personalized Medicine & Cannabinoids

CURE Pharmaceutical and Therapix Biosciences signed a memorandum of understanding to enter into a research collaboration with Assuta Medical Centers Ltd. The companies will collaborate to advance, research, develop and commercialize potential therapeutic products in the fields of personalized medicine and cannabinoids. As agreed to in the MOU, the Companies intend to formalize the pooling of professional, scientific, financial resources and expertise, in order to benefit from each of its respective advantages and capabilities to develop new therapeutic products in the fields of personalized medicine and cannabinoids. Specifically, CURE and Therapix will provide support and expertise in the development of pharmaceutical products, while Assuta will support the early research and development of potential projects through its research and facilities.

CURE Pharmaceutical Appoints Tracy Ryan to Advisory Board

CURE Pharmaceutical Holding Corp. announced the appointment of CannaKids Founder and CEO Tracy Ryan to its advisory board.

CURE Pharmaceutical and CannaKids Announce Research Collaboration with Technion Research and Development Foundation Ltd. on Cancer-Fighting Cannabinoids

CURE Pharmaceutical announced that the CURE and the CannaKids partnership has entered into a strategic research collaboration with Technion Research and Development Foundation Ltd. in order to research how different cannabinoid compounds within cannabis strains can be used to treat various subtypes of cancer. Researchers from CURE’s Pharmaceutical Cannabinoid Division and Technion’s Laboratory of Cancer Biology and Cannabinoid Research will work together to research and identify how varying cannabinoid compounds within cannabis strains can affect various cancer subtypes. The results of the research will be used to predict how to match a cancer subtype with an effective cannabis extract in order to optimize treatment efficacy. Technion’s lab group recently discovered two new pathways that have been activated by cannabis extracts in cancer cells. Technion is looking forward to this partnership and working with CURE to continue uncovering the vast therapeutic potential of the cannabinoids found in various cannabis species. Accumulating evidence indicates that cannabinoids have antitumor effects, as several studies have demonstrated the use of cannabinoids in being able to regress different cancer types. This research collaboration with CURE will help the company with their goal of determining which cannabis strains might be used to tackle different cancer cells and what cannabinoid compounds within the plant are responsible for the ability to kill these cells.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 15, 2016
Makkanotti Group Corp.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CURE Pharmaceutical Holding Corp., please visit www.curepharmaceutical.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.